2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Triple Negative Breast Neoplasms
3
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma
1
Melanoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid
1
Leukemia
1
Head and Neck Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Breast Neoplasms
1
Adrenocortical Carcinoma
1
Interventions
Cytarabine
14
fludarabine
13
venetoclax
11
Imatinib Mesylate
9
Cyclophosphamide
8
Azacitidine
8
fludarabine phosphate
7
Busulfan
7
Whole-Body Irradiation
6
Tacrolimus
6
Mycophenolic Acid
6
thymoglobulin
4
ponatinib
4
nilotinib
4
Sirolimus
4
Peripheral Blood Stem Cell Transplantation
4
Methotrexate
4
asciminib
3
aldesleukin
3
Melphalan
3
Interleukin-2
3
Idarubicin
3
Granulocyte Colony-Stimulating Factor
3
Filgrastim
3
Decitabine
3
Bone Marrow Transplantation
3
Antilymphocyte Serum
3
zosuquidar trihydrochloride
2
gilteritinib
2
enasidenib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Myeloid
×
IPI-549
×
Clear all
NCT07439211
2026-03-03
GAVEL
Dana-Farber Cancer Institute
Phase 1
Not yet recruiting
48 enrolled